-
Mashup Score: 53
The first series of chimeric antigen receptor T (CAR-T) cell therapy products were approved in 2017 to 2019 and have shown remarkable efficacy in both clinical trials and the real-world setting, but at the cost of prolonged patient hospitalization. As the toxicity management protocols were refined, the concept of cellular therapy administered in the outpatient setting gained steam, and single institutions began to perform certain aspects of CAR-T monitoring in the outpatient setting for select patients.
Source: www.astctjournal.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 26Early CAR-T Cells expansion is associated with prolonged PFS for patients with RRMM treated with ide-cel: a retrospective monocentric study. - 2 month(s) ago
The outcome of patients with relapsed and refractory multiple myeloma (RRMM) previously treated with the three main classes of myeloma therapy [immunomodulatory drugs (Imids), proteasome inhibitors (PI), and anti-CD38 antibodies (anti-CD38)] remains poor. However, in the KarMMa trial1, the use of idecabtagene vicleucel (ide-cel), an autologous B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell therapy (CAR-T) showed improved response with prolonged overall survival (OS) and progression-free survival (PFS) among heavily treated patients.
Source: www.astctjournal.orgCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 16Clinical Outcomes and Toxicity in Older Adults Receiving Chimeric Antigen Receptor T-cell Therapy - 3 month(s) ago
Chimeric antigen receptor T-cell (CAR-T) therapy has transformed the treatment landscape for relapsed and refractory hematological malignancies.1 A subset of patients with B-cell non-Hodgkin lymphomas (NHL) and multiple myeloma with historically dismal prognoses will experience durable remissions with CAR-T.2-7 However, CAR-T is associated with unique toxicities such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) and can result in intensive health care utilization.
Source: www.astctjournal.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 24Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Patients with Relapsed or Refractory CD20+ B Cell Lymphoma - 4 month(s) ago
Despite the multiple therapies currently available for patients with relapsed B cell malignancies, including those targeting CD19, outcomes are still poor for nonresponders. Approximately one-third of patients with diffuse large B cell lymphoma (DLBCL) will develop relapsed/refractory (R/R) disease to initial therapy.1 Second-line intensive chemotherapy for R/R disease is either infeasible or ineffective in approximately 70% of R/R DLBCL patients. Other aggressive CD20+ B cell non-Hodgkin lymphomas (NHLs) with similar treatment challenges include primary mediastinal B cell lymphoma, grade 3b follicular lymphoma (FL), transformed histology FL, and mantle cell lymphoma.
Source: www.astctjournal.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 38Outcomes of ATG-PTCY-CSA vs. ATG-based Prophylaxis for 10/10 HLA Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation - 4 month(s) ago
For 10/10 human leukocyte antigen (HLA)-matched unrelated donor (MUD) peripheral blood (PB) allo-HCT, anti-thymocyte globulin (ATG) combined with other immunosuppressive agents is broadly used in Europe for GVHD prevention1. Prospective data have demonstrated that ATG effectively depletes donor and recipient T-cells reducing the risk of graft rejection and GVHD1-6. Nevertheless, using ATG has been associated with non-desirable adverse outcomes such as infectious complications and delayed immune reconstitution7-9.
Source: www.astctjournal.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 6
Since 2021, 2 B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapies—idecabtagene vicleucel (ide-cel; Bristol Myers Squibb), and ciltacabtagene autoleucel (cilta-cel; Janssen Biotech)—have been approved by the US Food and Drug Administration (FDA) for relapsed or refractory multiple myeloma (RRMM) after 4 or more prior lines of therapy including an immunomodulatory drug (IMiD), a proteasome inhibitor (PI), and an anti-CD38 antibody [1–3]. The 2 products have shown unprecedented activity in RRMM, but relapse remains common in the late-line setting, where many patients have bulky, rapidly growing high-risk disease that may decrease both efficacy and safety.
Source: www.astctjournal.orgCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 2Improved Long-Term Net Survival after Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies over Two Decades - 5 month(s) ago
For more than 30 years, allogeneic (allo-) hematopoietic cell transplantation (HCT) has played a role in the curative treatment of hematologic malignant and non-malignant diseases. Over the past 2 decades, practices in HCT have changed with new hematopoietic cell sources or donors, including cord blood (CB), peripheral blood (PB), and haploidentical transplantation; the development of reduced-intensity conditioning; advances in the prevention and treatment of graft-versus-host disease (GVHD) and infection; and a higher resolution and number of loci tested for HLA matching [1].
Source: www.astctjournal.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 27Simple Score of Albumin and CRP Predicts High Grade Toxicity in Patients with Multiple Myeloma Receiving CAR-T Therapy - 5 month(s) ago
Chimeric antigen receptor T cells (CAR-T) targeting the B-cell maturation antigen (BCMA) have transformed the care of patients with relapsed/refractory (R/R) multiple myeloma (MM). Outcomes reported in pivotal studies have led to the approval of two anti-BCMA CAR-T therapy products, idecabtagene vicluecel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), which have demonstrated significant improvements over prior standard of care in patients with triple-class exposed (TCE) RRMM.1-4 The response rates to these therapies range between 73-98%.
Source: www.astctjournal.orgCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 36Outcomes of Autologous Stem Cell Transplantation in Patients with Ultra-High-Risk Multiple Myeloma - 5 month(s) ago
The therapeutic landscape of multiple myeloma (MM) has been rapidly changing with the availability of immunomodulatory drugs (IMiDs), proteasome inhibitors, and anti-CD38 monoclonal antibodies, with median overall survival (OS) now exceeding 10 years in most newly diagnosed MM (NDMM) patients [1]. However, the outcomes of NDMM patients are heterogeneous and influenced by multiple clinical and cytogenetic risk factors. The International Myeloma Working Group classifies t(4;14), t(14;16), del(17p), and gain/amplification of 1q as high-risk chromosomal abnormalities (HRMM) that confer a poor prognosis [2].
Source: www.astctjournal.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 10Demographics, Motivations, and Experiences of Participants in Transplantation or Cellular Therapy Fellowships - 6 month(s) ago
Recent American Society for Transplantation and Cellular Therapy guidelines have sought to establish clinical and research expectations for participants in blood and marrow transplantation (BMT) and cellular therapy (CT) fellowships. However, little is known about participants in BMT/CT fellowships and the value they find from this additional training. We wanted to characterize the demographics, motivations, and experiences of recent participants in BMT/CT fellowships. We developed a 27-item online survey addressing backgrounds, application processes, training experiences, and perceived benefits among physicians who had started a clinical U.S.-based BMT/CT fellowship between 2012 to 2021.
Source: www.astctjournal.orgCategories: General Medicine News, Partners & KOLsTweet
CAR T-Cell Therapy in the Outpatient Setting: An Expert Panel Opinion from the ASTCT @ASTCT_Journal @ASTCT @MediHumdani #bmtsm #CARTcell https://t.co/hONgQdWyWe